A groundbreaking study has revealed a potential breakthrough in treating narcolepsy type 1 (NT1). Researchers have found that oveporexton, an oral orexin receptor 2 agonist, significantly improves cognitive function in adults with NT1. This discovery comes from a secondary analysis of a phase 2 clinical trial, which focused on the cognitive benefits of oveporexton over 8 weeks of daily dosing. The results are particularly promising, showing moderate- to large-magnitude effects on attention, memory, and executive function. This study, led by Gert Jan Lammers, MD, PhD, highlights the potential of oveporexton as a treatment for cognitive symptoms in NT1 patients. The findings were published in JAMA Neurology and presented at the 2025 SLEEP Annual Meeting, where they showcased oveporexton's ability to reduce microsleep rates and delay the first occurrence of microsleep in NT1 patients. These results not only address cognitive improvements but also suggest a broader impact on the quality of life for individuals with NT1.
